<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774952</url>
  </required_header>
  <id_info>
    <org_study_id>RMC-5552-001</org_study_id>
    <nct_id>NCT04774952</nct_id>
  </id_info>
  <brief_title>Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC 5552 Monotherapy in Adult Subjects With Relapsed/Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revolution Medicines, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revolution Medicines, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and&#xD;
      pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult&#xD;
      participants with relapsed/refractory solid tumors and to identify the recommended Phase 2&#xD;
      dose (RP2D).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, Phase 1/1b study of RMC-5552 monotherapy in participants&#xD;
      with advanced relapsed or refractory solid tumors. The study will include 2 components: 1) a&#xD;
      Dose-Escalation Component for participants with relapsed or refractory solid tumors and 2) a&#xD;
      Dose-Expansion Component for participants with relapsed or refractory solid tumors harboring&#xD;
      certain specific mutations/rearrangements that result in hyperactivation of the mTOR pathway.&#xD;
      Participants will be treated until disease progression per RECIST v1.1, unacceptable&#xD;
      toxicity, or other criteria for withdrawal are met, whichever occurs first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Incidence, nature, and severity of treatment-emergent AEs and serious AEs, including incidence and severity of findings in laboratory values or vital signs for RMC-5552 monotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>21 days</time_frame>
    <description>Incidence and nature of DLTs with RMC-5552 monotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Peak plasma concentration of RMC-5552</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Time to achieve peak plasma concentration of RMC-5552</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Area under the plasma concentration time curve of RMC-5552</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Elimination half-life of RMC-5552</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Ratio of accumulation of RMC-5552 from a single dose to steady state with repeated dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall response rate of RMC-5552 per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Duration of response of RMC-5552 per RECIST v1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>RMC-5552</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RMC-5552 for IV administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMC-5552</intervention_name>
    <description>RMC-5552 for IV administration</description>
    <arm_group_label>RMC-5552</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants (male or female) â‰¥18 years of age&#xD;
&#xD;
          -  Participants who have advanced solid tumors that have failed, are intolerant to, or&#xD;
             are considered ineligible for standard of care anticancer treatments including&#xD;
             approved drugs for oncogenic drivers in their tumor type&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          -  Participants in the Dose-Expansion Component must have molecular aberrations in the&#xD;
             mTOR pathway&#xD;
&#xD;
          -  Adequate hematologic, hepatic and renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected leptomeningeal or brain metastases or spinal cord compression&#xD;
&#xD;
          -  Primary central nervous system (CNS) tumors&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Active, clinically significant interstitial lung disease or pneumonitis&#xD;
&#xD;
          -  Subjects with abnormal fasting glucose, type 1 diabetes, or uncontrolled type 2&#xD;
             diabetes are excluded.&#xD;
&#xD;
          -  Subjects with stomatitis or mucositis of any grade&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Revolution Medicines, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Revolution Medicines, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Revolution Medicines, Inc.</last_name>
    <phone>(650) 779-2300</phone>
    <email>CT-Inquiries@RevMed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Quines, MD</last_name>
      <phone>714-456-6244</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kim Inocencio</last_name>
      <phone>(714) 456-8549</phone>
      <email>ucstudy@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sai-Hong Ignatius Ou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Martinez</last_name>
      <phone>916-734-6447</phone>
      <email>axmartinez@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Riess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Francisco - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Zigman</last_name>
      <phone>415-885-3728</phone>
      <email>Erika.zigman@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Swati Sudarsan</last_name>
      <phone>(415) 885-3728</phone>
      <email>Swati.Sudarsan@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Pamela Munster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nevena Ugrenovic</last_name>
      <phone>813-745-2025</phone>
      <email>nevena.ugrenovic@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Eric Haura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Frederickson</last_name>
      <phone>646-888-4888</phone>
      <email>frederie@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Alison Schram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Phase1-Referrals@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Susanna Ulahannan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-339-4214</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Howard Burris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Seton Medical Center at University of Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Simon</last_name>
      <phone>512-495-5419</phone>
      <email>lmsimon@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Anna Capasso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PIK3CA</keyword>
  <keyword>PTEN</keyword>
  <keyword>TSC1/2</keyword>
  <keyword>STK11</keyword>
  <keyword>MTOR</keyword>
  <keyword>MYC</keyword>
  <keyword>MAPK</keyword>
  <keyword>advanced solid tumor</keyword>
  <keyword>advanced solid malignancies</keyword>
  <keyword>melanoma</keyword>
  <keyword>skin cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>endometrium/uterus cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Neoplasms, Squamous Cell</keyword>
  <keyword>Carcinoma, Squamous Cell</keyword>
  <keyword>Esophageal Neoplasms</keyword>
  <keyword>Carcinoma, Bronchogenic</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Neoplasms, Glandular and Epithelial</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Esophageal Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>4EBP1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

